Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Dec 2:15:1482005.
doi: 10.3389/fimmu.2024.1482005. eCollection 2024.

Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study

Na Zhou #  1 , Yuwei Hua #  1 , Yuping Ge #  1 , Qiang Wang  2 , Chenyu Wang  1 , Jia He  3 , Luo Zhao  3 , Shuangni Yu  4 , Junfang Yan  5 , Lin Zhao  1 , Li Li  3 , Chunmei Bai  1
Affiliations
Clinical Trial

Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study

Na Zhou et al. Front Immunol. .

Abstract

Background: The application of neoadjuvant immunotherapy in the treatment of esophageal cancer needs further exploration. This study aimed to investigate the safety and effectiveness of tislelizumab, an anti-PD-1 antibody, combined with chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (LA-ESCC).

Methods: In this phase II study, patients with clinical stages of II-IVA (T3-T4 and/or node positive) potentially resectable LA-ESCC were enrolled. Patients received neoadjuvant tislelizumab and chemotherapy every 3 weeks for 4 cycles before surgery and adjuvant tislelizumab for 9 months. The primary endpoint was pathological complete response (pCR) rate. Secondary endpoints included R0 resection, disease free survival (DFS), adverse events (AE), and biomarkers for predicting efficacy.

Results: The study included 30 patients. 25 patients completed neoadjuvant chemoimmunotherapy and underwent surgery, 96% with R0 resection. The pCR and MPR rate was 44% and 52%. The 6-month and 1-year DFS rate was 100% and 75.3%. 43.3% patients experienced severe (grade 3-4) treatment-related adverse events (TRAEs) and 5 patients developed severe immune-related adverse events (irAEs). Further exploration found that a group of peripheral lymphocyte subsets increased significantly after 2 cycles of neoadjuvant therapy in patients who achieved pCR, suggesting the importance of dynamic monitoring of circulating lymphocyte.

Conclusions: The combination of perioperative tislelizumab and neoadjuvant chemotherapy has achieved an encouraging pCR rate and demonstrated a manageable safety profile in patients with potentially resectable ESCC.

Clinical trial registration: https://www.chictr.org.cn/, identifier ChiCTR2100043772.

Keywords: esophageal squamous cell carcinoma; immunotherapy; neoadjuvant chemotherapy; perioperative treatment; tislelizumab.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Consort diagram.
Figure 2
Figure 2
Changes of overall tumor staging, T staging and N staging before and after neoadjuvnat treatment according to the TNM classification.
Figure 3
Figure 3
The Kaplan-Meier analysis for disease-free survival (A) and overall survival (B) in the treated population.
Figure 4
Figure 4
Difference of changes in lymphocyte subsets before and after 2 cycles of neoadjuvant treatment between pCR and non-pCR group. (A) Lymph cells, (B) NK cells, (C) CD8+T cells, (D) CD8+CD28+T cells, (E) CD8+DR+T cells, and (F) CD8+CD38+T cells.
See this image and copyright information in PMC

References

    1. Abnet CC, Arnold M, Wei W-Q. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. (2018) 154:360–73. doi: 10.1053/j.gastro.2017.08.023 - DOI - PMC - PubMed
    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2021) 71:209–49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Kato K, Ito Y, Daiko H, Ozawa S, Ogata T, Hara H, et al. . A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. J Clin Oncol. (2022) 40:238–8. doi: 10.1200/JCO.2022.40.4_suppl.238 - DOI
    1. Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. . Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. (2015) 16:1090–8. doi: 10.1016/S1470-2045(15)00040-6 - DOI - PubMed
    1. Hall PS, Swinson D, Cairns DA, Waters JS, Petty R, Allmark C, et al. . Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal cancer: the GO2 phase 3 randomized clinical trial. JAMA Oncol. (2021) 7:869–77. doi: 10.1001/jamaoncol.2021.0848 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources